HAE icon

Haemonetics

60.85 USD
-2.14
3.40%
Updated Feb 7, 12:01 PM EST
1 day
-3.40%
5 days
-10.45%
1 month
-21.71%
3 months
-29.68%
6 months
-29.01%
Year to date
-22.39%
1 year
-21.09%
5 years
-49.29%
10 years
44.37%
 

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $47.1M | Put options by funds: $21.1M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

4% less capital invested

Capital invested by funds: $4.67B [Q2] → $4.46B (-$208M) [Q3]

7% less repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 112

2.24% less ownership

Funds ownership: 110.74% [Q2] → 108.5% (-2.24%) [Q3]

4% less funds holding

Funds holding: 316 [Q2] → 302 (-14) [Q3]

18% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 55

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$95
56%
upside
Avg. target
$110
80%
upside
High target
$120
97%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Mike Matson
56% 1-year accuracy
69 / 123 met price target
77%upside
$108
Buy
Maintained
7 Feb 2025
Barrington Research
Michael Petusky
52% 1-year accuracy
37 / 71 met price target
56%upside
$95
Outperform
Maintained
7 Feb 2025
JP Morgan
Rohin Patel
0% 1-year accuracy
0 / 1 met price target
91%upside
$116
Overweight
Initiated
6 Dec 2024
Raymond James
Andrew Cooper
23% 1-year accuracy
3 / 13 met price target
97%upside
$120
Strong Buy
Upgraded
8 Nov 2024

Financial journalist opinion

Based on 10 articles about HAE published over the past 30 days

Neutral
Seeking Alpha
23 hours ago
Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities Michael Petusky - Barrington Research Larry Solow - CJS Securities Operator Good day, and welcome to the Haemonetics Third Quarter Fiscal Year 2025 Conference Call and Webcast. At this time, all participants are in a listen-only-mod.
Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 day ago
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
Zacks Investment Research
1 day ago
Haemonetics (HAE) Q3 Earnings Meet Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago.
Haemonetics (HAE) Q3 Earnings Meet Estimates
Neutral
PRNewsWire
1 day ago
Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Positive
Zacks Investment Research
2 weeks ago
Here's Why Haemonetics (HAE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Positive
Zacks Investment Research
2 weeks ago
HAE or ABT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
HAE or ABT: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
2 weeks ago
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
Neutral
PRNewsWire
3 weeks ago
Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A
BOSTON , Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemonetics' portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics' manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at Haemonetics' manufacturing facility in Tijuana, Mexico.
Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A
Neutral
PRNewsWire
4 weeks ago
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025
BOSTON , Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025.
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025
Positive
Zacks Investment Research
4 weeks ago
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Charts implemented using Lightweight Charts™